rituximab

RME Sverige Published on Dec 19, 2017 Geraldine (Jo) Cambridge, PhD, Dep. Medicine, University College, London on B-cell depletion with Rituximab.

Following the news of the null result of the Norwegian Phase III trial, and interest in how this impacts the planned UK trial, I thought it might be useful to open a thread for this. The microsite for this UK rituximab trial and associated B-cell research is on Invest in ME Research Centre of...

Reflecting, in part, on the impact of the news of the Rituximab null result. https://tipsforme.wordpress.com/2017/11/24/attacked-by-hope/

Terrible news from Marky90 at PR: http://forums.phoenixrising.me/index.php?threads/rituximab-phase-iii-negative-result.56244/

I'm amazed I never heard of this! It was uploaded a year ago and has had only 1,500 views. Maria is my hero(ine)! She's the reason we got a rituximab trial, IMO. She's a previously bedbound medical doctor who recovered from her ME/CFS following rtx treatment in a pilot study by Fluge and...

Anomalous microbiome and metabolic profiling in ME/CFS-patients Prof Maureen Hanson, Cornell University, USA From 1:10:47 ME/CFS and the immune system. Where are we now? Geraldine (Jo) Cambridge, PhD, Dep. Medicine, University College, London From 5:33

Rituximab (RituxME) Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series Øystein Fluge and Olav Mella BMC Neurology 2009 Link to article Benefit from B-Lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab in...